Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority…

Overview of attention for article published in Neuropsychiatric Disease and Treatment, August 2017

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

policy: 1 policy source
twitter: 2 X users

facebook: 1 Facebook page

Citations

dimensions_citation: 14 Dimensions

Readers on

mendeley: 67 Mendeley

Summary Policy documents X Facebook Dimensions citations

So far, Dimensions has found 14 publications that cite this research output.

14

The most recent citing publications are shown below. View all 14 publications that cite this research output on Dimensions.

Clinical effectiveness of paliperidone palmitate 3‐monthly and 1‐monthly as monotherapy in patients with schizophrenia: A retrospective cohort study based on the Medicaid claims database

Article in Neuropsychopharmacology Reports (September 2024)

Model-Informed Clinical Development of Once-Every-6-Month Injection of Paliperidone Palmitate in Patients with Schizophrenia: A Pharmacometric Bridging Approach (Part I)

Article in European Journal of Drug Metabolism and Pharmacokinetics (May 2024)

Factors Associated with Symptom Stabilization that Allow for Successful Transition from Once-Monthly Paliperidone Palmitate to Three-Monthly Paliperidone Palmitate: A Post Hoc Analysis Examined Clinical Characteristics in Chinese Patients with Schizophrenia

Article in CNS Drugs (January 2024)